<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03528512</url>
  </required_header>
  <id_info>
    <org_study_id>2017-363</org_study_id>
    <nct_id>NCT03528512</nct_id>
  </id_info>
  <brief_title>IN Ketamine vs IN Midazolam and Fentanyl for Laceration Repair</brief_title>
  <official_title>Comparison of Sedation, Pain, and Care Provider Satisfaction Between the Use of Intranasal Ketamine Versus Intranasal Midazolam and Fentanyl During Laceration Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Beaumont Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Often, repair of the cuts (laceration repair) proves to be traumatic for the children and the&#xD;
      parents. Nasal spray (Intranasal/IN) approaches for procedural pain reduction, such as during&#xD;
      dental work, have been demonstrated to make drug administration painless and well tolerated.&#xD;
      We are comparing IN ketamine to IN midazolam and fentanyl for pain and reducing anxiety&#xD;
      during repair of cuts in children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children frequently present to pediatric emergency center (PEC) with cuts of different body&#xD;
      parts. Often, repair of the cuts (laceration repair) proves to be traumatic for the children&#xD;
      and the parents alike. Ideally, repair of the cuts should be as painless and free from&#xD;
      anxiety as possible. To work towards this goal, different analgesic (pain drugs) and sedative&#xD;
      ( to calm patients down) management strategies use intravenous (into the vein), intramuscular&#xD;
      ( into the muscle) and, more recently, intranasal (into the nostrils) routes. Unfortunately,&#xD;
      intravenous access is hard to establish and may be painful for the child. The intramuscular&#xD;
      route is often similarly painful. Due to the rich blood supply and large surface area of the&#xD;
      nasal vestibule, intranasally (IN) administered medications are highly absorbed. IN&#xD;
      approaches for procedural pain reduction, such as during dental work, have been demonstrated&#xD;
      to make drug administration painless and well tolerated, making it an attractive potential&#xD;
      alternative to commonly used intravenous and intramuscular approaches. In several small&#xD;
      research studies, high doses of intranasal ketamine (9 mg/kg) produce adequate sedation&#xD;
      during laceration repair with minimal side effects. A recent study compared IN ketamine,&#xD;
      midazolam, fentanyl or combination of these drugs for pain management and urgent analgesia&#xD;
      sedation, and demonstrated that they are effective and safe, reporting that ~60% of study&#xD;
      participants sustained mild to moderate sedation. Unfortunately, there are not enough studies&#xD;
      done to evaluate the sedation effect of IN ketamine for laceration repair. Small studies&#xD;
      (Tsze and Nemeth) showed that IN ketamine is an effective alternative but no studies are done&#xD;
      to compare combination IN midazolam and fentanyl to IN ketamine. Our null hypothesis is that&#xD;
      there is no difference in sedation scores during laceration repair when comparing the use of&#xD;
      IN ketamine to IN midazolam and IN fentanyl.&#xD;
&#xD;
      We will recruit a total of 30 pediatric patients (6 months - 10 y age) in a randomized&#xD;
      double-blinded pilot study of IN ketamine alone or combined IN midazolam and IN fentanyl for&#xD;
      laceration repair, comparing levels of pain and sedation scores using validated pediatric&#xD;
      metrics as the primary outcomes. In addition, we will assess comparative nurse and physician&#xD;
      satisfaction in each of these two groups. Understanding the relative effectiveness of these&#xD;
      two approaches will help us identify a safe, effective, and easily administrable method to&#xD;
      manage pain and anxiety, thereby, improving patient experience and outcomes during the often&#xD;
      traumatic laceration repair procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Staffing for study was eliminated&#xD;
  </why_stopped>
  <start_date type="Actual">September 4, 2018</start_date>
  <completion_date type="Actual">February 6, 2019</completion_date>
  <primary_completion_date type="Actual">February 6, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double blinded control trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>A randomization list created by an online randomization tool will be used to assign participants to a treatment arm (in random blocks of 4, 6, and 8). As participants are enrolled in the study, they will be assigned to the next available sequential treatment arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sedation Score</measure>
    <time_frame>up to 30 minutes</time_frame>
    <description>The primary outcome variable is the maximum sedation score as measured by the University of Michigan Sedation Scale. This scale consists of an ordinal scale from 0 being awake and alert and 4 being unarousable. Medians will be calculated for each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Children With Maximum Sedation Score</measure>
    <time_frame>Up to 30 minutes</time_frame>
    <description>The proportion of children who receive a maximum sedation score of either 1 or 2 (without distinguishing between those values)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores During Laceration Repair</measure>
    <time_frame>Up to 30 minutes</time_frame>
    <description>The effect of IN ketamine vs IN midazolam + IN fentanyl on pain scores during laceration repair using either Face, Legs, Activity, Cry, Consolability (FLACC) Scale or Faces Scale pain scale depending for patient age, each a Likert scale from 0 being no pain to 10 being worst pain, median scores for each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nurse and Physician Satisfaction</measure>
    <time_frame>Up to 30 minutes</time_frame>
    <description>Nurse and physician satisfaction will be assessed by a survey which will be filled in the end of the sedation. Response to overall experience question score on Likert scale where 1 is poor and 5 is Excellent. Proportion of responders giving answers of 4 or 5 will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Failure</measure>
    <time_frame>Up to 30 minutes</time_frame>
    <description>Rates of failure to repair laceration due to agitation or intolerable pain with the switch to intravenous medications will be compared between two groups. Percentage failure will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vitals</measure>
    <time_frame>up to 30 minutes</time_frame>
    <description>Proportion of children who have any significant change in vitals during analgosedation (any desaturation - Oxygen saturation &lt; 90, and hypotension per age-related norms) will be compared between the two groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Laceration of Skin</condition>
  <arm_group>
    <arm_group_label>IN ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IN midazolam and fentanyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)</description>
    <arm_group_label>IN ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam and fentanyl</intervention_name>
    <description>Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)</description>
    <arm_group_label>IN midazolam and fentanyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric patients 6 months to 10 years who required laceration repair in the&#xD;
             pediatric emergency center.&#xD;
&#xD;
          -  Laceration should be less than 5 cm long, require 2 or more sutures and no consult&#xD;
             subspeciality consult for repair.&#xD;
&#xD;
          -  Topical anesthetic (lidocaine-epinephrine-tetracaine topical solution/XAP) will be&#xD;
             applied to all lacerations for 20 minutes duration before giving the intranasal&#xD;
             medications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 6 months&#xD;
&#xD;
          -  Documented allergy or adverse effect to ketamine, midazolam or fentanyl&#xD;
&#xD;
          -  Epistaxis&#xD;
&#xD;
          -  Partial upper airway obstruction&#xD;
&#xD;
          -  Oxygen requirement via nasal cannula&#xD;
&#xD;
          -  Acute mental status changes (e.g. obtunded or somnolent)&#xD;
&#xD;
          -  Documented increased intracranial pressure or increased ocular pressure&#xD;
&#xD;
          -  Documented porphyria&#xD;
&#xD;
          -  Previously involved in the study&#xD;
&#xD;
          -  Parent or patient refusal&#xD;
&#xD;
          -  Acutely compromised vitals (hypotension, desaturations, respiratory distress)&#xD;
&#xD;
          -  Any known heart disease&#xD;
&#xD;
          -  If any previous opioid use for analgesia during the visit&#xD;
&#xD;
          -  Need for staples&#xD;
&#xD;
          -  Scalp wounds&#xD;
&#xD;
          -  General trauma requiring additional sedation&#xD;
&#xD;
          -  Patients who received pain medications (acetaminophen or ibuprofen) before laceration&#xD;
             repair&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Levasseur, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beaumont Hospital - Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 5, 2018</study_first_submitted>
  <study_first_submitted_qc>May 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <results_first_submitted>May 11, 2021</results_first_submitted>
  <results_first_submitted_qc>July 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2021</results_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Margaret J Menoch, MD</investigator_full_name>
    <investigator_title>Pediatric ER Medical Clinical Faculty</investigator_title>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>analgesia</keyword>
  <keyword>pain control</keyword>
  <keyword>sedation</keyword>
  <keyword>intranasal ketamine</keyword>
  <keyword>intranasal midazolam</keyword>
  <keyword>intranasal fentanyl</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacerations</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03528512/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IN Ketamine</title>
          <description>Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)&#xD;
Ketamine: Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)</description>
        </group>
        <group group_id="P2">
          <title>IN Midazolam and Fentanyl</title>
          <description>Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)&#xD;
Midazolam and fentanyl: Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IN Ketamine</title>
          <description>Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)&#xD;
Ketamine: Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)</description>
        </group>
        <group group_id="B2">
          <title>IN Midazolam and Fentanyl</title>
          <description>Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)&#xD;
Midazolam and fentanyl: Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" spread="0.87"/>
                    <measurement group_id="B2" value="2" spread="0"/>
                    <measurement group_id="B3" value="2" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sedation Score</title>
        <description>The primary outcome variable is the maximum sedation score as measured by the University of Michigan Sedation Scale. This scale consists of an ordinal scale from 0 being awake and alert and 4 being unarousable. Medians will be calculated for each group.</description>
        <time_frame>up to 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IN Ketamine</title>
            <description>Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)&#xD;
Ketamine: Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)</description>
          </group>
          <group group_id="O2">
            <title>IN Midazolam and Fentanyl</title>
            <description>Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)&#xD;
Midazolam and fentanyl: Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)</description>
          </group>
        </group_list>
        <measure>
          <title>Sedation Score</title>
          <description>The primary outcome variable is the maximum sedation score as measured by the University of Michigan Sedation Scale. This scale consists of an ordinal scale from 0 being awake and alert and 4 being unarousable. Medians will be calculated for each group.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit=".5" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Children With Maximum Sedation Score</title>
        <description>The proportion of children who receive a maximum sedation score of either 1 or 2 (without distinguishing between those values)</description>
        <time_frame>Up to 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IN Ketamine</title>
            <description>Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)&#xD;
Ketamine: Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)</description>
          </group>
          <group group_id="O2">
            <title>IN Midazolam and Fentanyl</title>
            <description>Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)&#xD;
Midazolam and fentanyl: Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Children With Maximum Sedation Score</title>
          <description>The proportion of children who receive a maximum sedation score of either 1 or 2 (without distinguishing between those values)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores During Laceration Repair</title>
        <description>The effect of IN ketamine vs IN midazolam + IN fentanyl on pain scores during laceration repair using either Face, Legs, Activity, Cry, Consolability (FLACC) Scale or Faces Scale pain scale depending for patient age, each a Likert scale from 0 being no pain to 10 being worst pain, median scores for each group</description>
        <time_frame>Up to 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IN Ketamine</title>
            <description>Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)&#xD;
Ketamine: Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)</description>
          </group>
          <group group_id="O2">
            <title>IN Midazolam and Fentanyl</title>
            <description>Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)&#xD;
Midazolam and fentanyl: Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores During Laceration Repair</title>
          <description>The effect of IN ketamine vs IN midazolam + IN fentanyl on pain scores during laceration repair using either Face, Legs, Activity, Cry, Consolability (FLACC) Scale or Faces Scale pain scale depending for patient age, each a Likert scale from 0 being no pain to 10 being worst pain, median scores for each group</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4.5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nurse and Physician Satisfaction</title>
        <description>Nurse and physician satisfaction will be assessed by a survey which will be filled in the end of the sedation. Response to overall experience question score on Likert scale where 1 is poor and 5 is Excellent. Proportion of responders giving answers of 4 or 5 will be calculated.</description>
        <time_frame>Up to 30 minutes</time_frame>
        <population>Two provider surveys were available for each patient experience</population>
        <group_list>
          <group group_id="O1">
            <title>IN Ketamine</title>
            <description>Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)&#xD;
Ketamine: Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)</description>
          </group>
          <group group_id="O2">
            <title>IN Midazolam and Fentanyl</title>
            <description>Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)&#xD;
Midazolam and fentanyl: Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)</description>
          </group>
        </group_list>
        <measure>
          <title>Nurse and Physician Satisfaction</title>
          <description>Nurse and physician satisfaction will be assessed by a survey which will be filled in the end of the sedation. Response to overall experience question score on Likert scale where 1 is poor and 5 is Excellent. Proportion of responders giving answers of 4 or 5 will be calculated.</description>
          <population>Two provider surveys were available for each patient experience</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Failure</title>
        <description>Rates of failure to repair laceration due to agitation or intolerable pain with the switch to intravenous medications will be compared between two groups. Percentage failure will be reported.</description>
        <time_frame>Up to 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IN Ketamine</title>
            <description>Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)&#xD;
Ketamine: Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)</description>
          </group>
          <group group_id="O2">
            <title>IN Midazolam and Fentanyl</title>
            <description>Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)&#xD;
Midazolam and fentanyl: Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Failure</title>
          <description>Rates of failure to repair laceration due to agitation or intolerable pain with the switch to intravenous medications will be compared between two groups. Percentage failure will be reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vitals</title>
        <description>Proportion of children who have any significant change in vitals during analgosedation (any desaturation - Oxygen saturation &lt; 90, and hypotension per age-related norms) will be compared between the two groups.</description>
        <time_frame>up to 30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IN Ketamine</title>
            <description>Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)&#xD;
Ketamine: Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)</description>
          </group>
          <group group_id="O2">
            <title>IN Midazolam and Fentanyl</title>
            <description>Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)&#xD;
Midazolam and fentanyl: Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vitals</title>
          <description>Proportion of children who have any significant change in vitals during analgosedation (any desaturation - Oxygen saturation &lt; 90, and hypotension per age-related norms) will be compared between the two groups.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30-45 minutes</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IN Ketamine</title>
          <description>Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)&#xD;
Ketamine: Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)</description>
        </group>
        <group group_id="E2">
          <title>IN Midazolam and Fentanyl</title>
          <description>Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)&#xD;
Midazolam and fentanyl: Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated early because staffing was eliminated. No results analyzed due to population size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Margaret Menoch</name_or_title>
      <organization>William Beaumont Hospitals</organization>
      <phone>2489897289</phone>
      <email>margaret.menoch@beaumont.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

